Shanghai Junshi Biosciences Co., Ltd.(688180) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

688180 Shanghai Junshi Biosciences Co., Ltd.

Watchlist

29.00
-0.32-1.09%

Market Closed Mar 24 15:00 CST

28.59BMarket Cap-15.85P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

JUNSHI BIO (01877) returns the idle raised funds temporarily used to supplement working capital.
JUNSHI BIO (01877) announced that the third Board of Directors meeting will be held on March 28, 2024...
Zhitong Finance07:55 ET
Junshi Biosciences Gets Nod to Market Hepatocellular Carcinoma Drug
MT Newswires23:56 ET
Express News | Junshi Biosciences Announces Approval of Snda for Toripalimab in Combination With Bevacizumab for 1St-Line Treatment of Advanced Hepatocellular Carcinoma
Reuters23:53 ET
Junshi Biosciences Announces Approval of SNDA for Toripalimab in Combination With Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
GlobeNewswire23:53 ET
Express News | Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application for Toripalimab in Combination With Bevacizumab by Nmpa
ReutersMar 21 07:28 ET
Junshi Bio Gets China Nod to Trial Advanced Tumor Drug; Hong Kong Shares Down 4%
MT NewswiresMar 20 23:33 ET

Comments

Moomoo AI

Mar 6, 2024 06:54

The company's weak revenue trend, unprofitability, and rapid decline in share price reflect poor fundamentals. Last year's performance indicates unresolved challenges, worse than the annualized loss of 9% over the last half decade.

Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%

Spinee

Jan 17, 2024 16:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$Hang Seng Index (800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $REMEGEN (09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B (02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $VIVA BIOTECH (01873.HK)$ ...

Moomoo AI

Jan 9, 2024 09:54

Despite Shanghai Junshi Biosciences' weak revenue growth, its P/S ratio aligns with industry peers, indicating investors may be overlooking limited growth expectations and paying a premium. However, this could risk investments as the weak revenue outlook may eventually impact share prices.

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Out Of Tune With Revenues

Moomoo AI

Oct 28, 2023 08:26

Shanghai Junshi Biosciences carries rising debt yet has surplus liquid assets, offsetting risk. Despite having net cash, being a loss-maker might impact its financial health. Be cautious of investing until positive cash flow is seen.

Is Shanghai Junshi Biosciences (HKG:1877) Weighed On By Its Debt Load?

ETFWorldSavior

Jun 8, 2023 10:42

Columns Anxin International - Pharmaceutical Industry Biweekly Report: The results of Chinese medicine decoction pieces combined selection landing, 2023ASCO abstract released

Key points:
1. Hang Seng Index fell 2.57% in the first two weeks (2023/05/22 to 2023/06/02), with all 12 Hang Seng industries falling. Among them, the Hang Seng healthcare sector fell 1.51%, outperforming the Hang Seng Index by 1.06 percentage points, ranking third among the 12 Hang Seng industries
2. On May 22, the results of the f...

688180 Shanghai Junshi Biosciences Co., Ltd.

Trade Overview

Capital Trend

News

Comments

Market Insights